Gyre Therapeutics, INC Form 4 insider transactions

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 27 and 28, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 23 and 24, 2025, under a pre-arranged 10b5-1 trading plan.

Gyre Therapeutics President, Songjiang Ma, sold 4,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Gyre Therapeutics President, Songjiang Ma, sold 4,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Gyre Therapeutics President, Songjiang Ma, sold 4,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 10 and January 13, 2025, under a pre-arranged 10b5-1 trading plan.

Ma Songjiang, President of Gyre Therapeutics, files an amended SEC Form 4 to correct the transaction date of a common stock disposal.

Gyre Therapeutics President, Songjiang Ma, sold a total of 2,216 shares of common stock on January 6th and 7th, 2025, under a pre-arranged 10b5-1 trading plan.

Director Ping Zhang acquired options to purchase 52,000 shares of Gyre Therapeutics common stock on January 5, 2025.

Gyre Therapeutics President, Songjiang Ma, sold a total of 4,000 shares of common stock across three transactions, executed under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on December 30 and 31, 2024, under a pre-arranged trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between December 26 and December 27, 2024, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on December 23rd and 24th, 2024, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on December 19th and 20th, 2024, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between December 17 and December 18, 2024, under a pre-arranged 10b5-1 trading plan.

Director Rodney L Nussbaum acquired stock options for 52,000 shares of Gyre Therapeutics, Inc.

Director Renate Parry of Gyre Therapeutics, Inc. acquired 52,000 stock options on August 14, 2024, according to a recent SEC filing.

Director David M. Epstein acquired options to purchase 52,000 shares of Gyre Therapeutics stock on August 14, 2024.

Director Gordon Carmichael acquired stock options for 52,000 shares of Gyre Therapeutics common stock on August 14, 2024.

Songjiang Ma, President of Gyre Therapeutics, acquired options to purchase 26,000 shares of common stock on August 14, 2024.

Thomas Wilson Eastling, a director of Gyre Therapeutics, acquired options to purchase 26,000 shares of common stock on August 14, 2024.

Director Ying Luo acquired options to purchase 26,000 shares of Gyre Therapeutics common stock on August 14, 2024.

Ruoyu Chen, CFO of Gyre Therapeutics, acquired options to purchase 50,000 shares of the company's common stock on August 14, 2024.

Han Ying, CEO of Gyre Therapeutics, acquired options to purchase 341,000 shares of the company's common stock on August 14, 2024.

David M. Epstein, a director of Gyre Therapeutics, acquired stock options exercisable for 1,866 shares of common stock on August 6, 2024.

Director Nassim Usman exercised stock options and sold shares of Gyre Therapeutics, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Director Nassim Usman exercised stock options and sold shares of Gyre Therapeutics, Inc. on May 1, 2024, according to a recent SEC filing.

Director Nassim Usman exercised stock options and sold 20,000 shares of Gyre Therapeutics on April 1, 2024, according to a Form 4 filing with the SEC.

Director Rodney L. Nussbaum acquired stock options in Gyre Therapeutics, Inc. on March 20, 2024.

Director Nassim Usman exercised stock options and sold 20,000 shares of Gyre Therapeutics, Inc. common stock on March 15, 2024, according to a Form 4 filing with the SEC.